Biogen Canada Announces Broad Private Drug Plan Coverage For ZURZUVAE, Expanding Access For Eligible Patients With Postpartum Depression In Adults Following Childbirth
Benzinga Newsdesk 9 hours ago
GlobalNewsBiotechGeneral
Most national private drug plans now provide coverage for ZURZUVAE™, broadening access for eligible Canadian patients with private insurance coverage.Toronto, November 5, 2026 — Biogen Canada Inc. today announced that
- Most national private drug plans now provide coverage for ZURZUVAE™, broadening access for eligible Canadian patients with private insurance coverage.
Toronto, November 5, 2026 — Biogen Canada Inc. today announced that many group benefit health plans now reimburse ZURZUVAE™ (zuranolone), for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth, subject to individual plan eligibility and reimbursement requirements.